Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.432
AS - Asia 22.755
EU - Europa 12.094
SA - Sud America 3.263
Continente sconosciuto - Info sul continente non disponibili 1.734
AF - Africa 457
OC - Oceania 37
Totale 64.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.548
SG - Singapore 7.233
VN - Vietnam 5.025
IT - Italia 4.741
HK - Hong Kong 3.992
CN - Cina 2.989
BR - Brasile 2.460
RU - Federazione Russa 2.319
CA - Canada 1.418
IE - Irlanda 1.345
BD - Bangladesh 1.215
DE - Germania 918
SE - Svezia 613
FR - Francia 575
IN - India 460
GB - Regno Unito 366
AR - Argentina 330
FI - Finlandia 254
ID - Indonesia 251
KR - Corea 240
MX - Messico 192
IQ - Iraq 189
JP - Giappone 161
UA - Ucraina 154
NL - Olanda 149
AT - Austria 147
TR - Turchia 136
EC - Ecuador 125
PK - Pakistan 120
ZA - Sudafrica 120
CO - Colombia 102
SA - Arabia Saudita 99
ES - Italia 96
PH - Filippine 95
MY - Malesia 83
PL - Polonia 83
VE - Venezuela 71
JM - Giamaica 59
UZ - Uzbekistan 59
MA - Marocco 58
TN - Tunisia 56
PY - Paraguay 54
CR - Costa Rica 49
BE - Belgio 48
CL - Cile 47
TH - Thailandia 45
AE - Emirati Arabi Uniti 41
JO - Giordania 41
EG - Egitto 38
KE - Kenya 36
ET - Etiopia 34
NP - Nepal 30
AU - Australia 29
UY - Uruguay 29
NI - Nicaragua 28
RO - Romania 28
DK - Danimarca 27
PE - Perù 27
DZ - Algeria 26
HN - Honduras 26
CH - Svizzera 25
IR - Iran 25
KZ - Kazakistan 25
HU - Ungheria 24
LT - Lituania 24
TT - Trinidad e Tobago 24
CZ - Repubblica Ceca 23
LB - Libano 22
PS - Palestinian Territory 22
GT - Guatemala 19
OM - Oman 19
PT - Portogallo 19
IL - Israele 18
NO - Norvegia 17
AZ - Azerbaigian 16
TW - Taiwan 16
RS - Serbia 15
BO - Bolivia 13
NG - Nigeria 13
SY - Repubblica araba siriana 13
SV - El Salvador 12
CI - Costa d'Avorio 11
EE - Estonia 11
KG - Kirghizistan 11
QA - Qatar 11
AO - Angola 10
GR - Grecia 10
PR - Porto Rico 10
SN - Senegal 10
DO - Repubblica Dominicana 9
LV - Lettonia 9
PA - Panama 9
AL - Albania 8
BG - Bulgaria 8
BH - Bahrain 8
KW - Kuwait 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
BW - Botswana 7
GE - Georgia 7
Totale 62.906
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.935
Singapore 3.893
Ashburn 2.330
San Jose 2.087
Ho Chi Minh City 1.574
Milan 1.394
Dublin 1.295
Hanoi 1.237
Toronto 1.117
New York 869
Chandler 807
Chicago 782
Princeton 747
Council Bluffs 744
Los Angeles 666
Santa Clara 618
Hefei 602
The Dalles 591
Ann Arbor 580
Frankfurt am Main 557
Rome 551
Dallas 469
Lauterbourg 430
Beijing 356
Lawrence 291
Fairfield 289
Moscow 289
Buffalo 275
Altamura 268
Seoul 224
São Paulo 217
Helsinki 177
Seattle 171
Boardman 164
Da Nang 160
Jakarta 157
Wilmington 155
Figino 149
Nuremberg 148
Andover 147
Houston 146
Haiphong 143
Phoenix 125
Shanghai 122
San Diego 116
Naples 113
Turin 111
Cambridge 109
Woodbridge 107
Tokyo 100
Washington 96
Biên Hòa 92
Rio de Janeiro 92
Ha Long 91
Quận Bình Thạnh 91
Brooklyn 90
Ninh Bình 90
Montreal 88
London 87
Atlanta 84
Denver 77
Orem 76
Can Tho 75
Hải Dương 75
Columbus 74
Baghdad 73
Vienna 71
Guangzhou 68
Thái Nguyên 68
Salt Lake City 66
Munich 64
Philadelphia 64
San Francisco 62
Bắc Ninh 59
Pune 59
Brasília 57
Boston 56
Bologna 55
Warsaw 55
Mexico City 54
Bắc Giang 53
Vũng Tàu 53
Lappeenranta 51
San Mateo 51
Tashkent 49
Elk Grove Village 47
Miami 47
Charlotte 46
Dhaka 46
Belo Horizonte 45
Johannesburg 45
Newark 45
Kuala Lumpur 44
Queens 44
Brussels 43
Guayaquil 42
Istanbul 40
Quận Một 40
Buenos Aires 39
Jeddah 38
Totale 35.821
Salva come PNG Salva come JPEG
Nome #
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials 657
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 592
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 557
Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction between Supine Versus Upright Exercise Hemodynamic Testing 535
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes 518
Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction 481
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: Results from an Italian multicenter study 466
Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study 462
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 462
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 425
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 372
A matter of sex—persistent predictive value of MECKI score prognostic power in men and women with heart failure and reduced ejection fraction: a multicenter study 369
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 357
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials 356
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 354
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 332
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure 331
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 314
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 312
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 309
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 304
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 303
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 302
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial 297
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 287
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 286
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction 283
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists 278
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 273
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 252
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial 252
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 250
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 248
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 247
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 245
Right ventricular reserve in cardiopulmonary disease: A simultaneous hemodynamic and three-dimensional echocardiographic study 239
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 239
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 231
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure 226
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis 225
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 224
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 221
An uncommon and challenging finding regarding the tricuspid valve: Case report, clinical considerations, and practical management 220
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 220
Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects 213
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 212
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial 211
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 211
Evolocumab and clinical outcomes in patients with cardiovascular disease 208
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 206
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 204
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 203
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 202
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF 201
Finerenone in Heart Failure with Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial 198
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 195
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 191
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 189
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease 188
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 188
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 188
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities 186
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 186
The chronic heart failure evolutions: Different fates and routes 184
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF 184
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 181
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC 180
Exercise Right Ventricular-Pulmonary Arterial Coupling and Functional Outcome in Patients Undergoing Surgery for Secondary Ischemic Mitral Regurgitation 179
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 178
Finerenone and Atrial Fibrillation in Heart Failure A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 176
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis 175
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 175
Prognostic Value of sST2 in Heart Failure 173
A 57-year-old man with rapidly progressive pulmonary hypertension 172
Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial 168
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 165
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review 165
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 164
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 163
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 162
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction 161
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study 160
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 160
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 158
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 158
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 157
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels 157
Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial 155
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 153
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 153
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study 151
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 150
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 149
Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome 149
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity 147
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study 147
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug 147
Sacubitril/valsartan, a new and effective treatment of heart failure with reduced ejection fraction [Sacubitril/valsartan, una nuova ed efficace terapia dello scompenso cardiaco a funzione sistolica ridotta] 146
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 146
Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis 145
Totale 24.486
Salva come PNG Salva come JPEG
Categoria #
all - tutte 245.334
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 245.334
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.721 0 0 0 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/202512.162 466 1.221 441 471 1.283 473 1.104 347 1.518 1.639 946 2.253
2025/202632.457 4.379 3.430 1.888 2.627 2.724 1.395 3.931 1.451 2.079 2.286 2.509 3.758
2026/20278.466 1.621 2.064 4.378 403 0 0 0 0 0 0 0 0
Totale 64.772